Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882396 | 0.71 | CYP19A1 (0.46) | KCNA5CYP19A1CYP11B2CYP3A4 | |
| SCHEMBL3130718 | 0.68 | CYP11B2 (0.45) | CYP19A1CYP2A6CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL11666741 | 0.67 | CYP19A1 (0.47) | KCNA5KCNH2CYP19A1CYP11B2CYP3A4 | |
| SCHEMBL21761343 | 0.67 | CYP11B2 (0.67) | CYP2A6CYP11B2CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL30541935 | 0.67 | CYP11B2 (0.67) | CYP2A6CYP11B2CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL5649209 | 0.67 | MEN1 (0.42) | KCNA5KCNH2CYP2A6CHRNB2CHRNA4 | |
| SCHEMBL27609994 | 0.66 | CYP19A1 (0.55) | KCNA5CYP19A1CYP11B2CYP3A4 | |
| SCHEMBL5646072 | 0.66 | LMNA (0.41) | KCNA5KCNH2CYP19A1CYP11B2CHRNB2 | |
| SCHEMBL5378828 | 0.66 | SLC6A4 (0.42) | KCNA5KCNH2HDAC3HDAC1HDAC2 | |
| SCHEMBL3235238 | 0.65 | CYP19A1 (0.55) | KCNA5CYP19A1CYP2A6CYP11B2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994875-B1 | 3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | TARGACEPT INC (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6624173-B1 | Characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) treated by | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6525065-B1 | Central nervous system disorders; administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo(2.2.1)heptane, or a 1-aza-7-(3-pyridyl)bicyclo(3.2.2) nonane, or a 1-aza-2-(3-pyridyl)bicyclo(2.2.2)octane | TARGACEPT, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-0994875-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999000385-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |